Adage Capital Partners
RLMD icon

Adage Capital Partners’s Relmada Therapeutics RLMD Stock Holding History

Adage Capital Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33M Hold
4,763,158
– – 0.05% 367
2026
Q1 		$33.2M Buy
4,763,158
+493,158
+12% +$2.33M 0.05% 346
2025
Q4 		$20.6M Buy
+4,270,000
New +$14.3M 0.03% 472

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners's RLMD Position: Q2 2026 in Review

Adage Capital Partners held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 4,763,158 shares worth $33M. The position accounts for 0.05% of the portfolio, ranked #367.

Adage Capital Partners first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $33.2M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Adage Capital Partners held 4,763,158 shares of Relmada Therapeutics worth $33M as of Q2 2026.
  • Adage Capital Partners left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.05% of Adage Capital Partners's portfolio in Q2 2026, its #367 holding.
  • Adage Capital Partners first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Adage Capital Partners's Relmada Therapeutics position peaked at $33.2M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.